Acumen Pharmaceuticals, Inc. — Investor Relations & Filings
Filings indexed
308
across all filing types
Latest filing
2026-05-12
Interim / Quarterly Rep…
Country
US
United States of America
Listing
US
ABOS
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for Alzheimer's disease. The company's approach is based on research into toxic soluble amyloid beta oligomers (AβOs), which are considered a primary driver of neurodegeneration associated with the disease. Its lead product candidate, sabirnetug (ACU193), is a monoclonal antibody designed to selectively target these toxic AβOs. Sabirnetug is being developed as a potential disease-modifying treatment for early Alzheimer's, with the goal of providing therapeutic benefits with an improved safety profile.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q - Acumen Pharmaceuticals, Inc. (0001576885) (Filer) | 2026-05-12 | English | |
| 8-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer) | 2026-05-12 | English | |
| 424B3 - Acumen Pharmaceuticals, Inc. (0001576885) (Filer) | 2026-04-01 | English | |
| S-8 - Acumen Pharmaceuticals, Inc. (0001576885) (Filer) | 2026-03-26 | English | |
| 8-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer) | 2026-03-26 | English | |
| 4 - ACUMEN PHARMACEUTICALS, INC. (0001576885) (Filer) | 2026-03-03 | English |
Browse filings by year
7 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 45341748 | 10-Q - Acumen Pharmaceuticals, Inc. (0001576885) (Filer) | 2026-05-12 | English | ||
| 45234267 | 8-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer) | 2026-05-12 | English | ||
| 33150382 | 424B3 - Acumen Pharmaceuticals, Inc. (0001576885) (Filer) | 2026-04-01 | English | ||
| 33052041 | S-8 - Acumen Pharmaceuticals, Inc. (0001576885) (Filer) | 2026-03-26 | English | ||
| 33047337 | 8-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer) | 2026-03-26 | English | ||
| 32894292 | 4 - ACUMEN PHARMACEUTICALS, INC. (0001576885) (Filer) | 2026-03-03 | English | ||
| 30667365 | 4 Filing | 2026-01-28 | English | ||
| 30667379 | 4 Filing | 2026-01-23 | English | ||
| 30667376 | 4 Filing | 2026-01-23 | English | ||
| 30667372 | 4 Filing | 2026-01-23 | English | ||
| 30667366 | 4 Filing | 2026-01-23 | English | ||
| 30667364 | 4 Filing | 2026-01-23 | English | ||
| 30667405 | 4 Filing | 2026-01-21 | English | ||
| 30667404 | 4 Filing | 2026-01-21 | English | ||
| 30667382 | 4 Filing | 2026-01-21 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
|
Adaptimmune Therapeutics PLC
Commercial-stage biopharma developing TCR T-cell therapies …
|
ADAP | GB | Manufacturing |
Acumen Pharmaceuticals, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34208/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34208 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34208 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34208 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34208}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Acumen Pharmaceuticals, Inc. (id: 34208)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.